Skip to content

Study · Non-randomized trial · n = 76 · 1999

3 results

[Cortexin effectiveness in circulatory encephalopathy].

Khavinson VKh, Morozov VG, Rybnikov VIu, Zakutskiĭ NG

Klinicheskaia meditsina1 Jan 1999

PMID10356917 (opens in a new tab)PepBankPUB-10356917
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with dyscirculatory encephalopathy, cortexin added to standard therapy improved reported psychoemotional, neurological and cognitive measures compared with standard therapy alone.

    In plain wordsIn patients with dyscirculatory encephalopathy, cortexin added to standard therapy improved reported function measures compared with standard therapy alone.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreasePsychoemotional, neurological and cognitive function
    Study

    n = 76

    Comparator
    Standard therapy alone
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · nasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    Cortexin NE produced a positive effect on psychoemotional state, neurological status, intellectual-mnestic and CNS functions.
    2 context sentences
    Summary · context
    A clinical trial of cortexin, a new peptide bioregulator of cerebral functions, in combined therapy of dyscirculatory encephalopathy (DE) stage I-II was made in 76 patients.
    Summary · context
    They were divided into two groups: a control group of 31 patients on standard therapy and the study group of 45 patients on standard therapy with adjuvant cortexin delivered via nasal electrophoresis (NE).
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with dyscirculatory encephalopathy, cortexin added to standard therapy increased rehabilitation efficiency by 22.7% compared with standard therapy alone.

    In plain wordsIn patients with dyscirculatory encephalopathy, cortexin improved rehabilitation efficiency compared with standard therapy alone.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseRehabilitation efficiency
    Study

    n = 76

    Comparator
    Standard therapy alone
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · nasal electrophoresisAs given in this study (human).

    Measurements

    Rehabilitation efficiency increase
    22.7%
    adjuvant cortexin

    Source sentences

    Summary
    Adjuvant cortexin aroused efficiency of rehabilitation in DE stage I and II by 22.7%.
    2 context sentences
    Summary · context
    A clinical trial of cortexin, a new peptide bioregulator of cerebral functions, in combined therapy of dyscirculatory encephalopathy (DE) stage I-II was made in 76 patients.
    Summary · context
    They were divided into two groups: a control group of 31 patients on standard therapy and the study group of 45 patients on standard therapy with adjuvant cortexin delivered via nasal electrophoresis (NE).
  3. 03HumanNon-randomized trialSafety outcome

    In patients with dyscirculatory encephalopathy, cortexin was well tolerated with no side effects reported.

    In plain wordsIn patients with dyscirculatory encephalopathy, cortexin was well tolerated and no side effects were reported.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableSide effects
    Study

    n = 45

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    It is well tolerated and has no side effects.
    2 context sentences
    Summary · context
    A clinical trial of cortexin, a new peptide bioregulator of cerebral functions, in combined therapy of dyscirculatory encephalopathy (DE) stage I-II was made in 76 patients.
    Summary · context
    They were divided into two groups: a control group of 31 patients on standard therapy and the study group of 45 patients on standard therapy with adjuvant cortexin delivered via nasal electrophoresis (NE).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.